RT @BeateHolz_MD: Detection of NRG1 #GeneFusions in Solid Tumors See our report on #NRG1 fusions across tumors led by @SushmaJonna. Acti…
@JanEhses @sentivcapital @Jiantkwazi @TradeTexasBig @avidresearch Hey Jan, could you help me find where you’re seeing 1% of PDAC is NRG+? The company’s referenced figures seemed high to me. When I looked in the literature it looked like <0.3%. Example s
RT @JBrosnanCashman: ICYMI -- @AliSchram just discussed this @CCR_AACR paper on NRG1 fusions during her presentation at #ASCO21. https://…
ICYMI -- @AliSchram just discussed this @CCR_AACR paper on NRG1 fusions during her presentation at #ASCO21. https://t.co/NFPPwD6DbH
I believe $MRUS will obtain eventual approval in NRG1+ Pancreatic and NSCLC, but not tumor-agnostic approval. Keep in mind this is a rare, genetically-defined subset (~0.3-0.8% of NSCLC, <0.3% elsewhere) https://t.co/I0fc0idrpz thx @MSollender for
RT @TumorBoardTues: #TumorBoardTuesday Thursday Case🎀 (Case from 04/06/21) Mini-tweetorial #2 https://t.co/rTV2ew9TRS
#TumorBoardTuesday Thursday Case🎀 (Case from 04/06/21) Mini-tweetorial #2 https://t.co/rTV2ew9TRS
RT @benweinbergmd: @TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et a…
RT @StephenVLiu: Reminder that #NRG1 fusions are rare but important drivers seen across solid tumors. Due to the size of the gene and its l…
RT @StephenVLiu: Reminder that #NRG1 fusions are rare but important drivers seen across solid tumors. Due to the size of the gene and its l…
RT @StephenVLiu: Reminder that #NRG1 fusions are rare but important drivers seen across solid tumors. Due to the size of the gene and its l…
RT @benweinbergmd: @TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et a…
RT @benweinbergmd: @TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et a…
RT @benweinbergmd: @TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et a…
RT @benweinbergmd: @TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et a…
RT @benweinbergmd: @TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et a…
@TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9 NRG1 fusions are seen at low frequency across malignancies: Jonna et al. Clinical Cancer Research 2019. @SushmaJonna @StephenVLiu @CCR_AACR https://t.co/uNGzQPRrqF https://t.co/dXXElMmT83
RT @StephenVLiu: Reminder that #NRG1 fusions are rare but important drivers seen across solid tumors. Due to the size of the gene and its l…
RT @StephenVLiu: Reminder that #NRG1 fusions are rare but important drivers seen across solid tumors. Due to the size of the gene and its l…
RT @StephenVLiu: Reminder that #NRG1 fusions are rare but important drivers seen across solid tumors. Due to the size of the gene and its l…
More on gene 🧬 fusions: Neuregulin-1 #NRG1 fusions are uncommon but potential therapeutic 🎯 across several tumor types #NSCLC #CRC #Gallbladercancer #PancreaticCancer & others @AACR @CCR_AACR
for more pan-targets!!!
@pashtoonkasi @OncoAlert @FightCRC @CCAlliance @marklewismd @ShaalanBeg @mtmdphd @agrothey @GIcancerDoc @aakonc @cancerassassin1 Yea, very rare- @StephenVLiu published a series with 1/1600 CRC, 3/600 in PDAC and 3/600 in cholangio..https://t.co/qT6OdsBpRi
RT @Dr_Ivanoncologo: #Cancer | Detección de fusiones de genes #NRG1 en #tumores sólidos
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
It must be hard to recruit trials for NRG1 fusion tumors. Is this now part of regular screening? https://t.co/Rx1C6xvjbm https://t.co/kwUftJpIcA
RT @BeateHolz_MD: Detection of NRG1 #GeneFusions in Solid Tumors See our report on #NRG1 fusions across tumors led by @SushmaJonna. Acti…
RT @BeateHolz_MD: Detection of NRG1 #GeneFusions in Solid Tumors See our report on #NRG1 fusions across tumors led by @SushmaJonna. Acti…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @BeateHolz_MD: Detection of NRG1 #GeneFusions in Solid Tumors See our report on #NRG1 fusions across tumors led by @SushmaJonna. Acti…
Detection of NRG1 #GeneFusions in Solid Tumors See our report on #NRG1 fusions across tumors led by @SushmaJonna. Actionable fusion with trials open and in development; seen across tumor types including #NSCLC, CRC, cholangio, pancreatic and more. https
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
Another relevant @CCR_AACR paper mentioned by @AliSchram in her #clinicaltrial presentation at #Targets19 https://t.co/NFPPwD6DbH
RT @carisls: Congratulations to @StephenVLiu who authored the Caris NRG1 paper. Dr. Liu was recently promoted to Lung Cancer Program Direct…
RT @carisls: Congratulations to @StephenVLiu who authored the Caris NRG1 paper. Dr. Liu was recently promoted to Lung Cancer Program Direct…
Congratulations to @StephenVLiu who authored the Caris NRG1 paper. Dr. Liu was recently promoted to Lung Cancer Program Director at @LombardiCancer, one of our #CarisPOA members. We are extremely honored to have him on our team! Read the #NRG1 article here
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
Detection of NRG1 Gene Fusions in Solid Tumors https://t.co/AO1crH9KCX
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
Strong work by @StephenVLiu and team!! I’m proud of you @SushmaJonna , Kodus my friend !!
RT @PasqualePisapia: A very interesting paper on #NRG1 fusions across tumors.... Congratulations @StephenVLiu.... @OncoAlert https://t.co/0…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
Another target!
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
A very interesting paper on #NRG1 fusions across tumors.... Congratulations @StephenVLiu.... @OncoAlert
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
RT @StephenVLiu: #OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Act…
#OncoAlert Formally published this week in @CCR_AACR is our report on #NRG1 fusions across tumors led by @SushmaJonna. Actionable fusion with trials open and in development; seen across tumor types including #NSCLC, CRC, cholangio, pancreatic and more. ht
Detection of NRG1 Gene Fusions in #NeuroendocrineTumors and other solid tumors https://t.co/3h1QKUmz94
Detection of NRG1 Gene Fusions in Solid Tumors https://t.co/h1d6LL5VJB
RT @StephenVLiu: #OncoAlert Online now @CCR_AACR , characterization of #NRG1 fusions across solid tumor types. Potential tumor agnostic act…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @DralexGva: Very impressive. Huge sample size. What comes next will be even more exciting. Bravo! https://t.co/NR5h9InXHM
RT @DralexGva: Very impressive. Huge sample size. What comes next will be even more exciting. Bravo! https://t.co/NR5h9InXHM
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
Very impressive. Huge sample size. What comes next will be even more exciting. Bravo!
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially acti…
RT @StephenVLiu: #OncoAlert Online now @CCR_AACR , characterization of #NRG1 fusions across solid tumor types. Potential tumor agnostic act…
#NRG1 characterization in #NSCLC and across tumor types - full manuscript now available online @CCR_AACR. Potentially actionable fusion, best found with RNA-seq. Will be one of the next tumor agnostic targets in oncology. #OncoAlert #PrecisionMedicine ht
Detection of NRG1 Gene Fusions in Solid Tumors https://t.co/3i0gKkixQz
RT @StephenVLiu: #OncoAlert Online now @CCR_AACR , characterization of #NRG1 fusions across solid tumor types. Potential tumor agnostic act…
RT @StephenVLiu: #OncoAlert Online now @CCR_AACR , characterization of #NRG1 fusions across solid tumor types. Potential tumor agnostic act…